Phase I/II Clinical Trial Combining FUS1-nanoparticles and Erlotinib in Stage IV Lung Cancer.

Trial Profile

Phase I/II Clinical Trial Combining FUS1-nanoparticles and Erlotinib in Stage IV Lung Cancer.

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 31 May 2018

At a glance

  • Drugs CNVN 202 (Primary) ; Erlotinib
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions
  • Sponsors Genprex
  • Most Recent Events

    • 31 May 2018 According to a Genprex media release, WIRB-Copernicus Group (WCG) will serve as the Institutional Review Board (IRB) and Institutional Biosafety Committee (IBC) for new clinical trial sites of this study
    • 08 May 2018 According to a Genprex media release, Accenture is supporting Genprex with clinical data management and submission-compliant CDISC deliverable activities for this trial.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top